1
|
Islam MT, Jang NH, Lee HJ. Natural Products as Regulators against Matrix Metalloproteinases for the Treatment of Cancer. Biomedicines 2024; 12:794. [PMID: 38672151 PMCID: PMC11048580 DOI: 10.3390/biomedicines12040794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 03/21/2024] [Accepted: 03/29/2024] [Indexed: 04/28/2024] Open
Abstract
Cancers are currently the major cause of mortality in the world. According to previous studies, matrix metalloproteinases (MMPs) have an impact on tumor cell proliferation, which could lead to the onset and progression of cancers. Therefore, regulating the expression and activity of MMPs, especially MMP-2 and MMP-9, could be a promising strategy to reduce the risk of cancers. Various studies have tried to investigate and understand the pathophysiology of cancers to suggest potent treatments. In this review, we summarize how natural products from marine organisms and plants, as regulators of MMP-2 and MMP-9 expression and enzymatic activity, can operate as potent anticancer agents.
Collapse
Affiliation(s)
- Md. Towhedul Islam
- Department of Chemistry, Faculty of Science, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh
| | - Nak Han Jang
- Department of Chemistry Education, Kongju National University, Gongju 32588, Chungcheongnam-do, Republic of Korea
| | - Hyuck Jin Lee
- Department of Chemistry Education, Kongju National University, Gongju 32588, Chungcheongnam-do, Republic of Korea
| |
Collapse
|
2
|
Hu J, Yu W, Pang C, Jin J, Pham NT, Manavalan B, Wei L. DrugormerDTI: Drug Graphormer for drug-target interaction prediction. Comput Biol Med 2023; 161:106946. [PMID: 37244151 DOI: 10.1016/j.compbiomed.2023.106946] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 03/29/2023] [Accepted: 04/15/2023] [Indexed: 05/29/2023]
Abstract
Drug-target interactions (DTI) prediction is a crucial task in drug discovery. Existing computational methods accelerate the drug discovery in this respect. However, most of them suffer from low feature representation ability, significantly affecting the predictive performance. To address the problem, we propose a novel neural network architecture named DrugormerDTI, which uses Graph Transformer to learn both sequential and topological information through the input molecule graph and Resudual2vec to learn the underlying relation between residues from proteins. By conducting ablation experiments, we verify the importance of each part of the DrugormerDTI. We also demonstrate the good feature extraction and expression capabilities of our model via comparing the mapping results of the attention layer and molecular docking results. Experimental results show that our proposed model performs better than baseline methods on four benchmarks. We demonstrate that the introduction of Graph Transformer and the design of residue are appropriate for drug-target prediction.
Collapse
Affiliation(s)
- Jiayue Hu
- School of Software, Shandong University, Jinan, China; Joint SDU-NTU Centre for Artificial Intelligence Research (C-FAIR), Shandong University, Jinan, China
| | - Wang Yu
- School of Software, Shandong University, Jinan, China; Joint SDU-NTU Centre for Artificial Intelligence Research (C-FAIR), Shandong University, Jinan, China
| | - Chao Pang
- School of Software, Shandong University, Jinan, China; Joint SDU-NTU Centre for Artificial Intelligence Research (C-FAIR), Shandong University, Jinan, China
| | - Junru Jin
- School of Software, Shandong University, Jinan, China; Joint SDU-NTU Centre for Artificial Intelligence Research (C-FAIR), Shandong University, Jinan, China
| | - Nhat Truong Pham
- Computational Biology and Bioinformatics Laboratory, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 16419, Gyeonggi-do, South Korea
| | - Balachandran Manavalan
- Computational Biology and Bioinformatics Laboratory, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 16419, Gyeonggi-do, South Korea.
| | - Leyi Wei
- School of Software, Shandong University, Jinan, China; Joint SDU-NTU Centre for Artificial Intelligence Research (C-FAIR), Shandong University, Jinan, China.
| |
Collapse
|
3
|
Berry SCL, Cohen SM, Corton JC, de Camargo JLV, Eisenbrand G, Fukushima S, Greim H, Weber K, Rietjens IMCM, Strupp C. Letter to the Editors regarding "10% body weight (gain) change as criterion for the maximum tolerated dose: A critical analysis". Regul Toxicol Pharmacol 2023; 139:105362. [PMID: 36828242 DOI: 10.1016/j.yrtph.2023.105362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 02/15/2023] [Indexed: 02/24/2023]
Affiliation(s)
| | - Samuel M Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA
| | - J Christopher Corton
- Center for Computational Toxicology and Exposure, Office of Research and Development, Environmental Protection Agency, Durham, NC, 27711, USA
| | | | - Gerhard Eisenbrand
- Department of Chemistry, Div of Food Chemistry & Toxicology, University of Kaiserslautern, Heidelberg, Germany
| | | | | | | | - Ivonne M C M Rietjens
- Division of Toxicology, Wageningen University and Research, Wageningen, the Netherlands
| | | |
Collapse
|
4
|
Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade. J Trop Med 2022; 2022:5794350. [PMID: 35309872 PMCID: PMC8933079 DOI: 10.1155/2022/5794350] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 12/13/2021] [Accepted: 02/19/2022] [Indexed: 12/12/2022] Open
Abstract
The ethnopharmacological information gathered over many centuries and the presence of diverse metabolites have made the medicinal plants as the prime source of drugs. Despite the positive attributes of natural products, there are many questions pertaining to their mechanism of actions and molecular targets that impede their development as therapeutic agents. One of the major challenges in cancer research is the toxicity exerted by investigational agents towards the host. An understanding of their molecular targets, underlying mechanisms can reveal their anticancer efficacy, help in optimal therapeutic dose selection, to mitigate their side effects and toxicity towards the host. The purpose of this review is to collate details on natural products that are recently been investigated extensively in the past decade for their anticancer potential. Besides, critical analysis of their molecular targets and underlying mechanisms on multiple cancer cell lines, an in-depth probe of their toxicological screening on rodent models is outlined as well to observe the prevalence of their toxicity towards host. This review can provide valuable insights for researchers in developing methods, strategies during preclinical and clinical evaluation of anticancer candidates.
Collapse
|
5
|
Peptide drugs for photopharmacology: how much of a safety advantage can be gained by photocontrol? FUTURE DRUG DISCOVERY 2020. [DOI: 10.4155/fdd-2019-0033] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Aim: To verify whether photocontrol of biological activity could augment safety of a chemotherapeutic agent. Materials & methods: LD50 values for gramicidin S and photoisomeric forms of its photoswitchable diarylethene-containing analogs were determined using mice. The results were compared with data obtained from cell viability measurements taken for the same compounds. Absorption, Distribution, Metabolism, and Elimination (ADME) tests using a murine cancer model were conducted to get insight into the underlying reasons for the observed in vivo toxicity. Results: While in vitro cytotoxicity values of the photoisomers differed substantially, the differences in the observed LD50 values were less pronounced due to unfavorable pharmacokinetic parameters. Conclusion: Despite unfavorable pharmacokinetic properties as in the representative case studied here, there is an overall advantage to be gained in the safety profile of a chemotherapeutic agent via photocontrol. Nevertheless, optimization of the pharmacokinetic parameters of photoisomers is an important issue to be addressed during the development of photopharmacological drugs.
Collapse
|
6
|
Estrada-Ortiz N, Lopez-Gonzales E, Woods B, Stürup S, de Graaf IAM, Groothuis GMM, Casini A. Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands. Toxicol Res (Camb) 2019; 8:885-895. [PMID: 32190293 PMCID: PMC7067241 DOI: 10.1039/c9tx00149b] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 09/19/2019] [Indexed: 12/13/2022] Open
Abstract
Gold-based compounds are of great interest in the field of medicinal chemistry as novel therapeutic (anticancer) agents due to their peculiar reactivity and mechanisms of action with respect to organic drugs. Despite their promising pharmacological properties, the possible toxic effects of gold compounds need to be carefully evaluated in order to optimize their design and applicability. This study reports on the potential toxicity of three experimental gold-based anticancer compounds featuring lansoprazole ligands (1-3) studied in an ex vivo model, using rat precision cut kidney and liver slices (PCKS and PCLS, respectively). The results showed a different toxicity profile for the tested compounds, with the neutral complex 2 being the least toxic, even less toxic than cisplatin, followed by the cationic complex 1. The dinuclear cationic gold complex 3 was the most toxic in both liver and kidney slices. This result correlated with the metal uptake of the different compounds assessed by ICP-MS, where complex 3 showed the highest accumulation of gold in liver and kidney slices. Interestingly compound 1 showed the highest selectivity towards cancer cells compared to the healthy tissues. Histomorphology evaluation showed a similar pattern for all three Au(i) complexes, where the distal tubular cells suffered the most extensive damage, in contrast to the damage in the proximal tubules induced by cisplatin. The binding of representative gold compounds with the model ubiquitin was also studied by ESI-MS, showing that after 24 h incubation only 'naked' Au ions were bound to the protein following ligands' loss. The mRNA expression of stress response genes appeared to be similar for both evaluated organs, suggesting oxidative stress as the possible mechanism of toxicity. The obtained results open new perspectives towards the design and testing of bifunctional gold complexes with chemotherapeutic applications.
Collapse
Affiliation(s)
- Natalia Estrada-Ortiz
- Dept. Pharmacokinetics , Toxicology and Targeting , Groningen Research Institute of Pharmacy , University of Groningen , A. Deusinglaan 1 , 9713AV Groningen , The Netherlands . ;
| | - Elena Lopez-Gonzales
- Dept. Pharmacokinetics , Toxicology and Targeting , Groningen Research Institute of Pharmacy , University of Groningen , A. Deusinglaan 1 , 9713AV Groningen , The Netherlands . ;
| | - Ben Woods
- School of Chemistry , Cardiff University , Main Building , Park Place , CF10 3AT Cardiff , UK
| | - Stefan Stürup
- Dept. of Pharmacy , University of Copenhagen , Universitetsparken 2 , 2100 Copenhagen , Denmark
| | - Inge A M de Graaf
- Dept. Pharmacokinetics , Toxicology and Targeting , Groningen Research Institute of Pharmacy , University of Groningen , A. Deusinglaan 1 , 9713AV Groningen , The Netherlands . ;
| | - Geny M M Groothuis
- Dept. Pharmacokinetics , Toxicology and Targeting , Groningen Research Institute of Pharmacy , University of Groningen , A. Deusinglaan 1 , 9713AV Groningen , The Netherlands . ;
| | - Angela Casini
- Dept. Pharmacokinetics , Toxicology and Targeting , Groningen Research Institute of Pharmacy , University of Groningen , A. Deusinglaan 1 , 9713AV Groningen , The Netherlands . ;
- School of Chemistry , Cardiff University , Main Building , Park Place , CF10 3AT Cardiff , UK
- Department of Chemistry , Technical University of Munich , Lichtenbergstr. 4 , 85748 Garching b. München , Germany
| |
Collapse
|
7
|
Balogh Sivars K, Sivars U, Hornberg E, Zhang H, Brändén L, Bonfante R, Huang S, Constant S, Robinson I, Betts CJ, Åberg PM. A 3D Human Airway Model Enables Prediction of Respiratory Toxicity of Inhaled Drugs In Vitro. Toxicol Sci 2019; 162:301-308. [PMID: 29182718 DOI: 10.1093/toxsci/kfx255] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Respiratory tract toxicity represents a significant cause of attrition of inhaled drug candidates targeting respiratory diseases. One of the key issues to allow early detection of respiratory toxicities is the lack of reliable and predictive in vitro systems. Here, the relevance and value of a physiologically relevant 3D human airway in vitro model (MucilAir) were explored by repeated administration of a set of compounds with (n = 8) or without (n = 7) respiratory toxicity following inhalation in vivo. Predictability for respiratory toxicity was evaluated by readout of cytotoxicity, barrier integrity, viability, morphology, ciliary beating frequency, mucociliary clearance and cytokine release. Interestingly, the data show that in vivo toxicity can be predicted in vitro by studying cell barrier integrity by transepithelial electrical resistance (TEER), and cell viability determined by the Resazurin method. Both read-outs had 88% sensitivity and 100% specificity, respectively, while the former was more accurate with receiver operating characteristic (ROC) AUC of 0.98 (p = .0018) compared with ROC AUC of 0.90 (p = .0092). The loss of cell barrier integrity could mainly, but not fully, be attributed to a loss of cell coverage in 6 out of 7 compounds with reduced TEER. Notably, these effects occurred only at 400 µM, at concentration levels significantly above primary target cell potency, suggesting that greater attention to high local lung concentrations should be taken into account in safety assessment of inhaled drugs. Thus, prediction of respiratory toxicity in 3D human airway in vitro models may result in improved animal welfare and reduced attrition in inhaled drug discovery projects.
Collapse
Affiliation(s)
| | - Ulf Sivars
- Respiratory, Inflammation and Autoimmunity
| | | | - Hui Zhang
- Pathology, Drug Safety and Metabolism
| | | | | | - Song Huang
- Epithelix Sàrl, CH-1228 Geneva, Switzerland
| | | | | | | | - Per M Åberg
- Regulatory Safety, Drug Safety and Metabolism
| |
Collapse
|
8
|
Bolon B, Baze W, Shilling CJ, Keatley KL, Patrick DJ, Schafer KA. Good Laboratory Practice in the Academic Setting: Fundamental Principles for Nonclinical Safety Assessment and GLP-Compliant Pathology Support When Developing Innovative Biomedical Products. ILAR J 2019; 59:18-28. [DOI: 10.1093/ilar/ily008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Revised: 02/26/2018] [Indexed: 11/12/2022] Open
Abstract
AbstractDevelopment of new biomedical products necessitates nonclinical safety assessment in animals as a means of assessing potential risk to human patients. Pivotal nonclinical safety studies that support human clinical trials are performed according to Good Laboratory Practice (GLP) guidelines, which are designed to ensure that the study was conducted under carefully controlled conditions using standardized and validated procedures that will yield a reliable, reproducible, and traceable data set. The GLP guidelines established by different regulatory agencies address organizational structure, personnel responsibilities, personnel training practices, quality assurance (ensuring compliance), facilities, equipment, standard operating procedures, study documentation (record keeping), and record and sample retention. Academic institutions engaging in nonclinical safety assessment on-site have multiple options for implementing a GLP quality system. This article outlines the rationale supporting the use of a GLP-compliant or GLP-like quality system in academia and reviews key concepts needed to efficiently and effectively implement GLP in the academic setting. Emphasis is given to provision of GLP-compliant pathology support as (1) pathology data are an essential component of GLP nonclinical safety testing, (2) familiarity with pathology-related GLP procedures typically is gained first outside the academic setting, and (3) microscopic pathology diagnoses and interpretations require special accommodations to ensure that they are undertaken in a GLP-compliant fashion.
Collapse
Affiliation(s)
| | - Wallace Baze
- University of Texas MD Anderson Cancer Center, Michale E. Keeling Center for Comparative Medicine and Research, Department of Veterinary Sciences, Bastrop, Texas
| | - Christopher J Shilling
- The Research Institute at Nationwide Children’s Hospital, Center for Clinical and Translational Science, Drug and Device Development Services, Columbus, Ohio
| | | | | | | |
Collapse
|
9
|
Dumouchel JL, Chemuturi N, Milton MN, Camenisch G, Chastain J, Walles M, Sasseville V, Gunduz M, Iyer GR, Argikar UA. Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route. Drug Metab Dispos 2018; 46:1670-1683. [DOI: 10.1124/dmd.118.082974] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 08/10/2018] [Indexed: 11/22/2022] Open
|
10
|
Prior H, Baldrick P, de Haan L, Downes N, Jones K, Mortimer-Cassen E, Kimber I. Reviewing the Utility of Two Species in General Toxicology Related to Drug Development. Int J Toxicol 2018. [PMCID: PMC5881785 DOI: 10.1177/1091581818760564] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
As part of the safety assessment of new drugs, the use of two species (a rodent and a nonrodent) for regulatory toxicology studies is the typical approach taken for small molecules. For biologics, species selection is dictated by pharmacological relevance, and single species toxicology packages (typically using the nonhuman primate) are common. The UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research and the Association of the British Pharmaceutical Industry are collaborating on a project to review the utility of two species in regulatory toxicology studies, with the aim to explore whether there are wider circumstances when data from a single species could be sufficient to enable safe progression in humans. An international working group consisting of 37 representatives from pharmaceutical and biotechnology companies, contract research organizations, academia, and regulatory bodies is coordinating a large-scale data sharing exercise to examine the potential for changes in current practice to reduce the number of species used for nonclinical safety testing at different stages of development. The challenge will be to determine whether two species toxicology adds significant value or whether in some instances data from a single species are sufficient (across a broader range of molecules than is currently the case) without compromising human safety.
Collapse
Affiliation(s)
- Helen Prior
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), London, United Kingdom
| | - Paul Baldrick
- Nonclinical and Biological Discovery Expert Network (NaBDEN), The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
| | - Lolke de Haan
- Nonclinical and Biological Discovery Expert Network (NaBDEN), The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
| | - Noel Downes
- Nonclinical and Biological Discovery Expert Network (NaBDEN), The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
| | - Keith Jones
- Nonclinical and Biological Discovery Expert Network (NaBDEN), The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
| | - Elisabeth Mortimer-Cassen
- Nonclinical and Biological Discovery Expert Network (NaBDEN), The Association of the British Pharmaceutical Industry (ABPI), London, United Kingdom
| | - Ian Kimber
- Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
| |
Collapse
|